

# A comparison between standard triple therapy and sequential therapy on eradication of *Helicobacter pylori* in uremic patients: A randomized clinical trial

Atieh Makhloogh<sup>1,2</sup>, Hafez Fakheri<sup>3</sup>, Ahmad Ramezani Farkhani<sup>4</sup>, Omid Seddighi<sup>5</sup>, Seyed Vahid Hossieni<sup>6</sup>,  
 Mohammad Khademloo<sup>7</sup>, Zohreh Bari<sup>4</sup>

<sup>1</sup>Departments of Nephrology, Imam Khomeini Hospital, <sup>2</sup>Department of Immunology, Biology Molecular and Cellular Research Center, <sup>3</sup>Gastroenterology, <sup>4</sup>Department of Internal Medicine, Mazandaran University of Medical Sciences, <sup>5</sup>Departments of Nephrology, <sup>6</sup>Gastroenterology, Imam Khomeini Hospital, <sup>7</sup>Community Medicine, Mazandaran University of Medical Sciences, Sari, Iran

## Abstract

**Background:** The prevalence of peptic ulcer disease in hemodialysis dependent patients is higher than the general population. These patients are also more prone to upper gastrointestinal bleeding. The aim of this study was to compare the effects of a standard triple therapy with a sequential therapy on *Helicobacter pylori* eradication in azotemic and hemodialysis patients.

**Materials and Methods:** Forty nine hemodialysis and azotemic patients, naïve to *H. pylori* treatment, were randomized into two groups to receive either standard triple therapy (pantoprazole 40 mg, amoxicillin 500 mg and clarithromycin 250 mg twice a day for 14 days) or a sequential therapy (pantoprazole 40 mg for 10 days, amoxicillin 500 mg twice a day for the first 5 days and clarithromycin 250 mg + tinidazole 500 mg twice a day just during the second 5 days). *H. pylori* eradication was evaluated by fecal *H. pylori* antigen assessment 8 weeks after the treatment.

**Results:** Of 49 patients, 45 patients (21 in triple therapy group and 24 in the sequential group) completed the study. Based on intention to treat analysis, *H. pylori* eradication rates were 66.7% (95% confidence interval [CI]: 47.8-85.5%) in standard triple therapy group and 84% (95% CI: 69.6-98.3%) in sequential therapy group ( $P = 0.34$ ). Per-protocol (PP) eradication rates were (95% CI: 76.2%- 89.3%) 54 and 87.5% (95% CI: 68.8-95.5%), respectively ( $P = 0.32$ ).

**Conclusion:** According to Maastricht III consensus report, the results of our study showed that sequential therapy might be a better choice compared with the standard triple therapy in azotemic and hemodialysis patients Iran. We propose to assess the effects of shorter-duration sequential therapy (less than 10 days) for *H. pylori* eradication.

**Key Words:** Azotemic, *Helicobacter pylori*, hemodialysis, sequential, triple therapy

### Address for correspondence:

Prof. Hafez Fakheri, Imam Khomeini Hospital, Amir Mazandarani Boulevard, Sari, Iran.

E-mail: fakher42@yahoo.com

Received: 26.12.2012, Accepted: 14.05.2013

Access this article online	
Quick Response Code:	Website: www.advbiores.net
	DOI: 10.4103/2277-9175.146372

## INTRODUCTION

World-wide, about 1.1 million people have chronic kidney disease (CKD) receiving hemodialysis. This population is growing at a rate of 0.7% per year due to advances in medical and dialysis techniques.<sup>[1]</sup> On the other hand, about 50% of the world's population is infected with *Helicobacter pylori*.<sup>[2]</sup> This rate even

Copyright: © 2014 Makhloogh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**How to cite this article:** Makhloogh A, Fakheri H, Farkhani AR, Seddighi O, Hossieni SV, Khademloo M, et al. A comparison between standard triple therapy and sequential therapy on eradication of *Helicobacter pylori* in uremic patients: A randomized clinical trial. Adv Biomed Res 2014;3:248.

exceeds 70% in some developing countries.<sup>[3]</sup> The infection plays an important role in some gastric conditions including peptic ulcer disease, gastric carcinoma and gastric mucosa associated-lymphoid tissue lymphoma, both in a healthy population and in those with chronic renal failure receiving hemodialysis or continuous ambulatory peritoneal dialysis.<sup>[4-7]</sup>

The studies reporting the prevalence of *H. pylori* in uremic patients are limited<sup>[8]</sup> and it seems to be equal or lower than the normal population.<sup>[7]</sup> However, the prevalence of peptic ulcer disease in hemodialysis patients infected with *H. pylori* is higher than the general population.<sup>[9]</sup> Since gastric mucosa of hemodialysis patients is fragile and anticoagulant therapy is inevitable during hemodialysis, these patients are more prone to upper gastrointestinal bleeding.<sup>[10]</sup> In order to prevent or to treat peptic ulcer disease in uremic patients, *H. pylori* eradication is recommended as the first line therapy.<sup>[11]</sup>

According to Maastricht III consensus report, first line therapy for *H. pylori* eradication is a standard triple therapy including a proton-pump inhibitor (PPI) + clarithromycin + either amoxicillin or metronidazole for 7-14 days.<sup>[12]</sup> Currently, the same regimen is recommended for hemodialysis patients, administered for 2 weeks.

However, in the general population, the eradication rate using standard triple therapy has fallen to 75-80% from the initial 90%.<sup>[13,14]</sup> Therefore, this regimen has been questioned and other therapies have been proposed.

Recently, sequential therapies have shown significant success rates in *H. pylori* eradication.<sup>[15-18]</sup> According to a meta-analysis including 3200 non-hemodialysis patients, sequential therapies were significantly more effective than standard triple therapies in *H. pylori* eradication.<sup>[15]</sup> We have recently shown 89.1% eradication rate by sequential therapy in non-uremic patients.<sup>[19]</sup>

In this study, we compared the effects of a standard triple therapy with a clarithromycin-containing sequential therapy on *H. pylori* eradication in azotemic and hemodialysis patients.

## MATERIALS AND METHODS

This study was an open label randomized clinical trial performed in Sari, situated in North of Iran from 2010 to 2011. The study protocol was approved by the Hospital Institutional Review Board and Ethics Committee (number: 88-4) and was registered in Iranian

registry of clinical trials (number: 138706211241n1). Also, informed consent was obtained from all participants.

Based on findings of previous studies and statistical consultation, our study had to include a minimum of 40 subjects. However, we randomly included 49 patients due to the usual poor compliance of CKD patients, which could result in some loss during the study.

The inclusion criteria were: CKD patients with a serum creatinine level of more than 2 mg/dl or a creatinine clearance ( $Cl_{cr}$ ) of 15-59 ml/min for at least 3 months and also hemodialysis patients undergoing 2-3 times dialysis per week for at least 3 months. They were all aged >18 years and complained of dyspepsia for at least 1 month and all were positive for *H. pylori* infection using tissue exam or rapid urease test. Also, they were all naïve to *H. pylori* treatment.

The exclusion criteria were history of sensitivity to penicillin or PPIs, non-steroidal anti-inflammatory drug use, taking H2-blockers and/or PPIs and/or antibiotics during the previous 4 weeks, history of upper gastrointestinal surgery, ketoconazole or steroids consumption, alcoholism, pregnancy, having severe heart disease (including myocardial infarction or ejection fraction  $\leq 30$ ), liver disease or malignancy.

### Endoscopic procedure and *H. pylori* assessment

All 49 patients had undergone an upper endoscopic examination (using Fujinon EG-250WR5 videogastroscope, Fuji Photo Optical Ltd, Japan). Three biopsies were taken from gastric body and antrum. *H. pylori* infection was confirmed by rapid urease test and histological evaluation of biopsy samples. Biopsies were stained using H and E and wright stains. If at least one of the two tests was positive, the patient was considered positive for *H. pylori* infection.

All patients were randomly enrolled to either of two groups using a computer-generated randomization: 25 patients received standard triple therapy pantoprazole, amoxicillin and clarithromycin (PAC): Pantoprazole 40 mg, amoxicillin 500 mg and clarithromycin 250 mg twice a day for 14 days and 24 patients received sequential therapy pantoprazole, amoxicillin- clarithromycin, tinidazole (PA-CT): Pantoprazole 40 mg twice a day for 10 days, amoxicillin 500 mg twice a day for the first 5 days and clarithromycin 250 mg + tinidazole 500 mg twice a day just during the second 5 days. The dosage of antibiotics was adjusted according to  $Cl_{cr}$  in CKD patients. The patients were asked to record any adverse effects of therapy. Compliance to treatment was considered excellent if patient took >80% of medications, good if

70-80% of prescribed drugs were used and moderate or bad if the patient used 60-70% or less than 60% the drugs, respectively. Adverse effects of therapy were considered as mild (not interfering with daily activities), moderate (partially interfering with daily activities) and severe (preventing daily activities).

Due to reported toxic effects of amoxicillin on renal function in CKD patients,<sup>[20]</sup> we measured creatinine and blood urea nitrogen at the beginning of treatment and also 1 and 4 weeks after therapy in all patients.

Due to the lower specificity of urease breath test in uremic patients,<sup>[21]</sup> we used fecal *H. pylori* antigen assessment to evaluate *H. pylori* eradication 8 weeks after the treatment. The test was performed by enzyme-linked immune-assay (Instrument: Lab systems Multiskan MS, Washington DC, USA; Kit: Catalog number: 7010, generic assay company, Dahlewitz, Germany) and the cut-off value was 0.1, which had >95% accuracy for detecting *H. pylori* infection.

Mean  $\pm$  SD and median values were calculated for continuous variables, whereas frequencies were measured for categorical variables. Continuous variables were analyzed using *t*-test and categorical variables were analyzed by Chi-square. Data were analyzed using Statistical Package for the Social Sciences software (version 14) by a statistician who was unaware of the patients' group. In order to calculate intention to treat eradication rate, all participants were included in the analysis, but only those who completed the whole protocol with more than 80% compliance to treatment were included in PER-protocol (PP) analysis. *P* values less than 0.05 were considered statistically significant.

**Table 1: Demographic characteristics of the patients at baseline**

Variable	Standard group (%)	Sequential group (%)	<i>P</i> value
Male/female	10/14 (41.7/58.3)	13/12 (52/48)	0.46
Age (mean $\pm$ SD) (years)	55.3 $\pm$ 18.04	54.54 $\pm$ 14.35	0.96
Weight	61.3 $\pm$ 13.11	68.93 $\pm$ 16.21	0.089
Height	154.48 $\pm$ 11.85	159.5 $\pm$ 12.27	0.11
History of DM	10 (41.7)	9 (36)	0.68
History of IHD	3 (12.5)	5 (20)	0.47
History of HTN	15 (62.5)	15 (60)	0.85
History of CVA	3 (12.5)	1 (4)	0.27
History of ADPKD	2 (8.3)	1 (4)	0.52
History of dialysis	16 (66.7)	12 (0.48)	0.18
History of GI bleeding	0	2 (8)	0.19
History of retinopathy	2 (8.3)	3 (12)	0.87
History of CABG	1 (4.2)	1 (4)	0.97

DM: Diabetes mellitus, IHD: Ischemic heart disease, HTN: Hypertension, CVA: Cerebro-vascular attack, ADPKD: Autosomal dominant poly-cystic kidney disease, CABG: Coronary artery bypass grafting, GI: Gastrointestinals

## RESULTS

Demographic characteristics of the patients at baseline are shown in Table 1 and endoscopic findings are shown in Table 2. Twenty eight patients were hemodialysis dependent: 16 patients in the standard therapy and 12 in sequential therapy groups.


Of 49 patients, 45 (21 in standard therapy group and 24 in sequential therapy group) completed the study.

Four patients of 49 patients were lost to second follow-up and did not perform S/E (three patients in standard therapy group and one in sequential therapy group). Three patients complained of adverse effects: One reported bitter taste due to triple therapy and two reported severe nausea caused by sequential treatment. The latter two patients were dialysis-dependent, one of whom stopped treatment due to side-effects. The remaining patients had more than 80% compliance to treatment.

According to intention to treat analysis, 16 patients (66.7%; 95% confidence interval [CI]: 47.8-85.5%) of the standard therapy group and twenty one (84%; 95% CI: 69.6-98.3%) of sequential therapy group had negative fecal *H. pylori* antigen test after treatment, which did not show a significant difference between the two groups (*P* = 0.34). PP eradication rates were 76.2% (95% CI: 54.6-89.3%) and 87.5% (95% CI: 68.8-95.5%), respectively (*P* = 0.32) [Table 3 Flow-chart 1].

Among 28 hemodialysis dependent patients, 26 patients completed the study (15 of 16 patients in standard therapy group and 11 of 12 patients in sequential therapy group). Eradication was achieved in 12 (80%) patients of standard therapy group and 10 (90.9%) patients of sequential therapy group and (*P* = 0.44).

Among 21 non-hemodialysis dependent patients (8 in standard and 13 in sequential groups), 19 patients



**Flow-chart 1: The study design and eradication rates during follow-up**

**Table 2: Endoscopic findings of the patients in both groups before therapy**

Endoscopic findings (%)	Standard group			Sequential group		
	60>Cl <sub>cr</sub> ≥30	30>Cl <sub>cr</sub> ≥15	Cl <sub>cr</sub> <15	60>Cl <sub>cr</sub> ≥30	30>Cl <sub>cr</sub> ≥15	Cl <sub>cr</sub> <15
Gastritis	0 (0.00)	1 (20)	4 (80)	1 (14.30)	4 (57.10)	2 (28.6)
Erosive gastritis	1 (16.70)	2 (33.30)	3 (50)	0 (0.00)	6 (75)	2 (25)
GU	0 (0.00)	0 (0.00)	1 (100)	0 (0.00)	0 (0.00)	2 (100)
Duodenitis	0 (0.00)	2 (33.30)	4 (66.70)	0 (0.00)	0 (0.00)	2 (100)
Erosive duodenitis	1 (50)	0 (0.00)	1 (50)	0 (0.00)	2 (50)	2 (50)
DU	0 (0.00)	1 (33.30)	2 (66.70)	0 (0.00)	0 (0.00)	1 (100)
Normal	0 (0.00)	0 (0.00)	1 (100)	0 (0.00)	0 (0.00)	1 (100)
Total	2 (8.30)	6 (25.00)	16 (66.70)	1 (4)	12 (48.00)	12 (48.00)

GU: Gastric ulcer, DU: Duodenal ulcer

**Table 3: *Helicobacter pylori* eradication rates in different stages of kidney disease according to ITT in both groups**

Drug diet	Dialysis	Stage 4	Stage 3	Total (%)
Standard group	12 of 15 (80)	3 of 4 (75)	1 of 2 (50)	16 of 21 (76.2)
Sequential group	10 of 11 (90.9)	10 of 12 (83.3)	1 of 1 (100)	21 of 24 (87.5)

ITT: Intention to treat

completed the study (six patients (75%) of standard therapy group and 13 patients (100%) of sequential therapy group). Eradication was achieved in four of six patients (66.7%) in standard therapy group and 11 of 13 patients (84.6%) in sequential therapy group ( $P = 0.37$ ).

Totally, 22 hemodialysis dependent patients (84.6%) eradicated *H. pylori* with both regimens while 15 non-hemodialysis dependent patients (78.9%) achieved eradication ( $P = 0.62$ ).

## DISCUSSION

According to our results, sequential therapy seems to be more effective than standard triple therapy in CKD patients, although it seems that the patients' compliance with sequential therapy is not as good as with standard regimen.

Upper gastrointestinal symptoms are common in uremic patients.<sup>[20]</sup> It has been shown that chronic renal failure, either prior to renal transplantation or in patients on hemodialysis, is a predisposing factor for gastro-duodenal mucosal lesions.<sup>[20]</sup> These gastrointestinal complications can be directly associated with *H. pylori* infection in uremic patients.<sup>[9]</sup>

Nowadays, eradication of *H. pylori* infection is recommended as the 1<sup>st</sup>-step in preventing and treating peptic ulcer disease, not only in patients with normal renal function, but also in uremic patients.<sup>[20-21]</sup> In recent studies, standard triple regimens had disappointing results and only few

hemodialysis dependent patients could achieve *H. pylori* eradication.<sup>[22]</sup>

According to a study by Wang *et al.* on 40 hemodialysis dependent patients, 7 day omeprazole-amoxicillin-clarithromycin (OAC) regimen could eradicate *H. pylori* in 86.8% of cases.<sup>[23]</sup> In addition, Tsukada *et al.* reported 82.1% eradication rate using the same regimen for 39 hemodialysis patients.<sup>[24]</sup> Sezer *et al.* showed a high eradication rate (94.1%) among 17 hemodialysis dependent patients using 14-day OAC regimen.<sup>[25]</sup> However, Itatsu *et al.* reported low eradication rate (72.7%) among 11 hemodialysis patients who had received 7-day lansoprazole-amoxicillin-clarithromycin.<sup>[21]</sup> On the other hand, Won studied the effects of low-dose OAC on 33 hemodialysis dependent patients and reported an eradication rate of 83.4%.<sup>[26]</sup>

Since amoxicillin and clarithromycin are primarily eliminated via the renal route, these antibiotics need a dosage adjustment based on Cl<sub>cr</sub> in patients with renal failure.<sup>[27]</sup> Toxic effects of amoxicillin on renal function in patients with chronic renal failure have been reported in various studies. The regimen of clarithromycin and lansoprazole without amoxicillin has succeeded only in 33.3% of patients.<sup>[20]</sup> Furthermore, 36.4% of patients with end-stage renal disease have been reported to have clarithromycin-resistant strains, which is significantly higher than renal disease is limited due to its toxic effects.<sup>[28]</sup>

Therefore, it seems that common standard regimens in CKD patients have fewer efficacies and more complications than normal populations.

In recent studies, a new regimen is introduced for eradication of *H. pylori* infection in peptic ulcer disease that uses a sequential order of drugs. This regimen has shown significant success rates, exceeding even 90% in the normal population.<sup>[29,30]</sup> A meta-analysis on 3200 non-hemodialysis patients showed that sequential therapies were significantly more effective than



standard triple therapies for *H. pylori* eradication.<sup>[15]</sup> Zullo *et al.* evaluated 1049 non-uremic patients with dyspepsia in two groups of standard and sequential regimens. He reported 92% eradication rate by sequential therapy versus 74% by standard therapy.<sup>[30]</sup> Studies by De Francesco and Hassan showed the same results.<sup>[29-31]</sup> The highest eradication rates using the sequential regimen has been shown in Italy, but reports from Asia have shown different results. Seyyedmajidi *et al.* compared the effects of a 14-day standard triple therapy with a new sequential therapy (omeprazol and amoxicillin for 14 days, ciprofloxacin just during the 1<sup>st</sup> week and furazolidone just during the 2<sup>nd</sup> week) on 39 patients with *H. pylori* infection. The eradication rates were 80% and 78.9% for standard triple therapy and sequential therapy, respectively.<sup>[32]</sup> In our previous study, *H. pylori* eradication rate in non-uremic patients was 89.1% by sequential therapy.<sup>[19]</sup>

In the present study, all patients using triple therapy had excellent compliance to treatment without any severe adverse effects leading to discontinuation of therapy. However, two patients (8%) in the sequential therapy group had severe side-effects and one of them discontinued therapy because of severe nausea. Lower doses of antibiotics and the simplicity of treatment might have been two reasons for excellent compliance in the triple therapy group, but the number of antibiotics and the complexity of therapy might have influenced compliance using sequential therapy.

Apart from compliance, antibiotic resistance is another factor influencing *H. pylori* eradication rates. One of the problems in renal failure patients is the probability of higher rates of antibiotic resistance since most of them have previously received different kinds of antibiotics due to impaired immune system. In hemodialysis dependent patients, even using lower doses of antibiotics or PPIs may lead to high plasma concentrations of the drugs. On the other hand, hemodialysis can remove PPIs and antibiotics from the body and therefore, decreasing the plasma level of drugs to lower than expected. Thus, it is essential to set an optimal dosing program to improve eradication rates. In addition, it is better to use antibiotics according to monitored levels of drugs to increase safety.

If we consider *H. pylori* infection as an infectious disease, the ideal regimen is one that can eradicate *H. pylori* infection in more than 95% of cases. Graham classified the efficacy of treatment according to per-protocol success as: (A) Excellent (>95% eradication rate), (B) good (90-95%), (C) fair (85-89%), (D) poor (81-84%) and (F) unacceptable ( $\leq 80\%$ ).<sup>[33]</sup> However, in practice, well-tolerated cost-effective

regimens with intention-to-treat eradication rates more than 80% are assumed ideal according to Maastricht III consensus report.<sup>[12]</sup>

According to our results, standard treatment is classified as group F (unacceptable) and sequential treatment as group C (fair) (76.2% vs. 87.5% according to PP analysis, respectively). Although there was no significant difference between the two regimens ( $P$  value = 0.346), it seems that the sequential regimen is more effective than standard regimen based on Dr. Graham's classification. In intention-to-treat analysis, the eradication rates were 66.7% and 84%, respectively, which was not significantly different between the two groups ( $P$  = 0.34). However, based on Maastricht III consensus report, sequential therapy can be clinically an ideal regimen for eradication of *H. pylori* infection in CKD patients due to achieving more than 80% success rate.

The main limitations of our study were the small number of patients and the unavailability of *H. pylori* culture; therefore, we cannot correlate the results with our regional resistance pattern. Furthermore, we could not assess the variations in plasma concentrations of the drugs after each dialysis course.

## CONCLUSION

Based on these results, it seems that sequential therapy might be a better choice compared to the standard regimen for CKD and hemodialysis patients in Iran. Further modifications are needed to improve sequential therapies in uremic and hemodialysis dependent patients to achieve better results in developing countries.

## ACKNOWLEDGMENT

The authors wish to thank Dr. Mohammad Reza Mahdavi his contribution to this study. This study was supported by a grant from Mazandaran University of Medical Sciences Sari, Iran and was the thesis of Ahmad Ramezani Farkhani in this Institute.

## REFERENCES

1. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. *J Am Soc Nephrol* 2002;13 Suppl 1:S37-40.
2. Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of *Helicobacter pylori* infection. *Helicobacter* 2008;13 Suppl 1:35-40.
3. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. *Eur J Gastroenterol Hepatol* 1995;7:427-33.
4. Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of *Helicobacter pylori* infection in long-term hemodialysis patients. *Kidney Int* 2009;75:96-103.
5. Gioè FP, Cudia B, Romano G, Cocchiara G, Li Vecchi V, Gioè MA, et al. Role and clinical importance of *Helicobacter pylori* infection in hemodialysis patients. *G Chir* 2008;29:81-4.

6. Suzuki H, Saito Y, Hibi T. *Helicobacter pylori* and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Updated review of clinical outcomes and the molecular pathogenesis. *Gut Liver* 2009;3:81-7.
7. Lentine KL, Parsonnet J, Taylor I, Wrono EM, Lafayette RA. Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. *Clin Exp Nephrol* 2006;10:55-62.
8. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Muñoz E. Meta-analysis: *Helicobacter pylori* eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. *Aliment Pharmacol Ther* 2004;19:617-29.
9. Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, et al. Gastro-duodenal lesions and *Helicobacter pylori* infection in uremic patients and renal transplant recipients. *Transplant Proc* 2007;39:1003-7.
10. Fábán G, Szigeti N, Kovács T, Nagy J. An unusual multiplex cause of severe gastrointestinal bleeding in a haemodialysed patient. *Nephrol Dial Transplant* 2000;15:1869-71.
11. Sugimoto M, Yamaoka Y. Review of *Helicobacter pylori* infection and chronic renal failure. *Ther Apher Dial* 2011;15:1-9.
12. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of *Helicobacter pylori* infection: The Maastricht III consensus report. *Gut* 2007;56:772-81.
13. Nam TM, Lee DH, Kang KP, Lee JH, Chung JI, Choi HC, et al. Clinical factors that potentially affect the treatment outcome of *Helicobacter pylori* eradication therapy with using a standard triple regimen in peptic ulcer patients. *Korean J Gastrointest Endosc* 2008;36:200-5.
14. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for *Helicobacter pylori* eradication. *Ann Intern Med* 2007;147:553-62.
15. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for *Helicobacter pylori* infection: Systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009;104:3069-79.
16. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for *Helicobacter pylori* infection: A meta-analysis. *J Clin Pharm Ther* 2009;34:41-53.
17. Jafri NS, Hornung CA, Howden CW. Meta-analysis: Sequential therapy appears superior to standard therapy for *Helicobacter pylori* infection in patients naive to treatment. *Ann Intern Med* 2008;148:923-31.
18. Sánchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for *Helicobacter pylori* eradication in clinical practice. *Am J Gastroenterol* 2008;103:2220-3.
19. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for *Helicobacter pylori* eradication in Iran: A randomized clinical trial. *Helicobacter* 2012;17:43-8.
20. Cocchiara G, Romano M, Buscemi G, Maione C, Maniaci S, Romano G. Advantage of eradication therapy for *Helicobacter pylori* before kidney transplantation in uremic patients. *Transplant Proc* 2007;39:3041-3.
21. Itatsu T, Miwa H, Nagahara A, Kubota M, Miyazaki A, Sato N, et al. Eradication of *Helicobacter pylori* in hemodialysis patients. *Ren Fail* 2007;29:97-102.
22. Ecclissato C, Marchioretto MA, Mendonça S, Godoy AP, Guersoni RA, Deguer M, et al. Increased primary resistance to recommended antibiotics negatively affects *Helicobacter pylori* eradication. *Helicobacter* 2002;7:53-9.
23. Wang YL, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen *Helicobacter pylori* infection and assess success of eradication therapy in hemodialysis patients. *Am J Kidney Dis* 2001;38:98-103.
24. Tsukada K, Miyazaki T, Katoh H, Masuda N, Ojima H, Fukai Y, et al. Seven-day triple therapy with omeprazole, amoxicillin and clarithromycin for *Helicobacter pylori* infection in haemodialysis patients. *Scand J Gastroenterol* 2002;37:1265-8.
25. Sezer S, Ibiş A, Ozdemir BH, Ozdemir FN, Külah E, Boyacıoğlu S, et al. Association of *Helicobacter pylori* infection with nutritional status in hemodialysis patients. *Transplant Proc* 2004;36:47-9.
26. Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, et al. *Helicobacter pylori* eradication with a 7-day low-dose triple therapy in hemodialysis patients. *Clin Exp Nephrol* 2010;14:469-73.
27. Kappel J, Calissi P. Nephrology. 3. Safe drug prescribing for patients with renal insufficiency. *CMAJ* 2002;166:473-7.
28. Fabrizi F, Martin P. *Helicobacter pylori* infection in patients with end-stage renal disease. *Int J Artif Organs* 2000;23:157-64.
29. De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, et al. The prolongation of triple therapy for *Helicobacter pylori* does not allow reaching therapeutic outcome of sequential scheme: A prospective, randomised study. *Dig Liver Dis* 2004;36:322-6.
30. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of *Helicobacter pylori* with a new sequential treatment. *Aliment Pharmacol Ther* 2003;17:719-26.
31. De Francesco V, Della Valle N, Stoppino V, Amoroso A, Muscatiello N, Panella C, et al. Effectiveness and pharmaceutical cost of sequential treatment for *Helicobacter pylori* in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 2004;19:993-8.
32. Seyyedmajidi M, Falaknazi K, Mirsattari D, Zojaji H, Roshani M, Lahmi F, et al. Correlation between creatinine clearance and *Helicobacter pylori* infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. *Arab J Gastroenterol* 2011;12:150-3.
33. Graham DY, Lu H, Yamaoka Y. A report card to grade *Helicobacter pylori* therapy. *Helicobacter* 2007;12:275-8.

**Source of Support:** Nil, **Conflict of Interest:** None declared.